lurasidone (Latuda)
Jump to navigation
Jump to search
Indications
- treatment of schizophrenia in adults
- mania[2]
- psychosis & agitation in the elderly[3]
- biopolar depression*
* copius television advertisement for using Lutuda to treat bipolar depression
Dosage
* do not exceed 40 mg in patients concurrently taking CYP3A4 inhibitor[3]
Pharmacokinetics
Adverse effects
- drowsiness, sedation
- agitation, tremors
- nausea
- no weight gain (per manufacturer)
- risk for death when used off-label to treat psychosis & agitation in the elderly
- black box warning[3]
- increased risk of hyperglycemia
- increased risk of cerebrovascular events
- increased risk of mortality in patients with dementia
- drug adverse effects of antipsychotic agents
- drug adverse effects of atypical antipsychotic agents
- drug adverse effects of psychotropic agents
Drug interactions
- drug interaction(s) of antipsychotics & dopamine receptor agonists
- drug interaction(s) of antipsycotics with benzodiazepines
- drug interaction(s) of gabapentinoid with psychotropic agent
Laboratory
More general terms
References
- ↑ Physician's First Watch for November 1, 2010 Massachusetts Medical Society http://www.jwatch.org
FDA NEWS RELEASE, Oct. 28, 2010 FDA approves Latuda to treat schizophrenia in adults http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm - ↑ Jump up to: 2.0 2.1 Deprecated Reference
- ↑ Jump up to: 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=213046
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11329364
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10074405
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9828361
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11237860
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9828360